Literature DB >> 14729536

The effect of deafferentation on cerebral blood flow response to acetazolamide.

Hiroshi Yamauchi1, Hidehiko Okazawa, Kanji Sugimoto, Yoshihiko Kishibe, Masaaki Takahashi.   

Abstract

BACKGROUND AND
PURPOSE: Decreased cerebral blood flow (CBF) response after acetazolamide administration may indicate increased cerebral blood volume (CBV) owing to reduced perfusion pressure from major cerebral artery steno-occlusive disease. However, decreased cerebral metabolic rate of oxygen (CMRO(2)) caused by neuronal damage or deafferentation may also decrease the CBF response to acetazolamide, which adds complexity to the assessment of autoregulatory vasodilatation. The purpose of this study was to investigate the relationship between CBF response to acetazolamide and CBV or CMRO(2) in a pure form of deafferentation, crossed cerebellar diaschisis (CCD).
METHODS: We used positron emission tomography to study 17 patients with unilateral supratentorial infarct and contralateral cerebellar hypoperfusion. The CBF response to acetazolamide was assessed by measuring baseline CBF and CBF 10 minutes after an intravenous injection of acetazolamide. Multivariate analysis was used to test the independent predictive value of the CBV and CMRO(2) at baseline with respect to the change of CBF during acetazolamide administration.
RESULTS: Multivariate analysis revealed that in CCD CBV was significantly and independently associated with the percent change of CBF during acetazolamide administration (P <.0001), whereas CMRO(2) was not.
CONCLUSION: In deafferentation, changes in CBV may account for variations in CBF response to acetazolamide and decreased CMRO(2) may not affect CBF response to acetazolamide expressed as the percent change.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14729536      PMCID: PMC7974156     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  26 in total

1.  Assessment of benzodiazepine receptors using iodine-123-labeled iomazenil single-photon emission computed tomography in patients with ischemic cerebrovascular disease. A comparison with PET study.

Authors:  Y Dong; H Fukuyama; H Nabatame; H Yamauchi; H Shibasaki; Y Yonekura
Journal:  Stroke       Date:  1997-09       Impact factor: 7.914

2.  Correction for the presence of intravascular oxygen-15 in the steady-state technique for measuring regional oxygen extraction ratio in the brain: 1. Description of the method.

Authors:  A A Lammertsma; T Jones
Journal:  J Cereb Blood Flow Metab       Date:  1983-12       Impact factor: 6.200

3.  Performance characteristics of a whole-body PET scanner.

Authors:  T R DeGrado; T G Turkington; J J Williams; C W Stearns; J M Hoffman; R E Coleman
Journal:  J Nucl Med       Date:  1994-08       Impact factor: 10.057

4.  Brain blood flow measured with intravenous H2(15)O. I. Theory and error analysis.

Authors:  P Herscovitch; J Markham; M E Raichle
Journal:  J Nucl Med       Date:  1983-09       Impact factor: 10.057

5.  Acetazolamide effect on vascular response in areas with diaschisis as measured by Tc-99m HMPAO brain SPECT.

Authors:  H Matsuda; S Tsuji; H Sumiya; S Hogashi; K Kinuya; N Tonami; K Hisada; J Yamashita
Journal:  Clin Nucl Med       Date:  1992-07       Impact factor: 7.794

6.  Long-term prognosis of medically treated patients with internal carotid or middle cerebral artery occlusion: can acetazolamide test predict it?

Authors:  S Kuroda; K Houkin; H Kamiyama; K Mitsumori; Y Iwasaki; H Abe
Journal:  Stroke       Date:  2001-09       Impact factor: 7.914

7.  Quantitative measurement of regional cerebral blood flow and oxygen metabolism in man using 15O and positron emission tomography: theory, procedure, and normal values.

Authors:  R S Frackowiak; G L Lenzi; T Jones; J D Heather
Journal:  J Comput Assist Tomogr       Date:  1980-12       Impact factor: 1.826

8.  Hypoperfusion and vasoreactivity in the thalamus and cerebellum after stroke.

Authors:  Y Sakashita; H Matsuda; K Kakuda; M Takamori
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

9.  Vascular reserve in chronic cerebral ischemia measured by the acetazolamide challenge test: comparison with positron emission tomography.

Authors:  T Nariai; R Suzuki; K Hirakawa; T Maehara; K Ishii; M Senda
Journal:  AJNR Am J Neuroradiol       Date:  1995-03       Impact factor: 3.825

Review 10.  Physiological determination of cerebrovascular reserves and its use in clinical management.

Authors:  H Yonas; R R Pindzola
Journal:  Cerebrovasc Brain Metab Rev       Date:  1994
View more
  5 in total

1.  Which CT perfusion parameter best reflects cerebrovascular reserve?: correlation of acetazolamide-challenged CT perfusion with single-photon emission CT in Moyamoya patients.

Authors:  N-J Rim; H S Kim; Y S Shin; S Y Kim
Journal:  AJNR Am J Neuroradiol       Date:  2008-07-10       Impact factor: 3.825

2.  Crossed cerebellar diaschisis after stroke identified noninvasively with cerebral blood flow-weighted arterial spin labeling MRI.

Authors:  Megan K Strother; Cari Buckingham; Carlos C Faraco; Daniel F Arteaga; Pengcheng Lu; Yaomin Xu; Manus J Donahue
Journal:  Eur J Radiol       Date:  2015-11-10       Impact factor: 3.528

3.  Task-evoked BOLD responses are normal in areas of diaschisis after stroke.

Authors:  Damien A Fair; Abraham Z Snyder; Lisa Tabor Connor; Binyam Nardos; Maurizio Corbetta
Journal:  Neurorehabil Neural Repair       Date:  2008-09-16       Impact factor: 3.919

4.  Crossed cerebellar diaschisis in acute stroke detected by dynamic susceptibility contrast MR perfusion imaging.

Authors:  D D M Lin; J T Kleinman; R J Wityk; R F Gottesman; A E Hillis; A W Lee; P B Barker
Journal:  AJNR Am J Neuroradiol       Date:  2009-02-04       Impact factor: 3.825

5.  Magnetic resonance perfusion imaging evaluation in perfusion abnormalities of the cerebellum after supratentorial unilateral hyperacute cerebral infarction.

Authors:  Pan Liang; Yunjun Yang; Weijian Chen; Yuxia Duan; Hongqing Wang; Xiaotong Wang
Journal:  Neural Regen Res       Date:  2012-04-25       Impact factor: 5.135

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.